Biotech-focused ETFs increasing weighting in the company strengthens the "BIVI stock forecast 2025" case for broader investor interest. This kind of passive inflow can steadily lift demand regardless of short-term sentiment shifts. While BioVie is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. While I understand the market’s worries, I don’t think the government will axe ACP – especially in an election year when incumbent politicians avoid rocking the boat on popular policies. But even if the ACP is eventually cut off, SurgePays stock seems to already have that risk priced in at these levels. The dispersion reflects high uncertainty but also upside potential if key markets open to the company’s products within the projected timeline.